Este es un estudio de fase 2/3, global, multicéntrico, abierto y de múltiples cohortes, diseñado para evaluar la seguridad y eficacia de terapias dirigidas o inmunoterapia como agentes únicos o en combinación en participantes con CPCNP irresecable, avanzado o metastásico con mutaciones somáticas oncogénicas o carga mutacional tumoral (TMB) positiva identificadas mediante un análisis de ADN tumoral circulante (ctDNA) por secuenciación de próxima generación (NGS) en sangre.
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
Participants will receive entrectinib 600 mg orally QD.
Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
Buenos Aires, Argentina
Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina